---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-021061"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T04:42:14.446422+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Arrowhead Q3 FY2022 revenue $32.4M, net loss $72.0M; pipeline progresses

## Summary
- Q3 FY2022 revenue $32.4M (down 29% YoY); net loss $72.0M ($0.68 loss per share) vs $29.9M loss prior year.
- Total cash & investments $582.4M, down from $613.4M at Sept 2021; operating loss $72.9M.
- Phase 2 fazirsiran: fibrosis regression in 58%, median 83% reduction in Z-AAT accumulation in liver.
- Initiated Phase 1/2a for ARO-MUC5AC and ARO-RAGE; Phase 2 GATEWAY for ARO-ANG3 in HoFH started.
- Hired Tracie Oliver as CCO; promoted Patrick O'Brien to COO; formed JV Visirna Therapeutics with Vivo Capital.

## SEC filing metadata
- accession: 0001628280-22-021061
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000162828022021061/0001628280-22-021061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000162828022021061/arwr-20220804.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-021061
- JSON: https://secwatch.observer/filing/0001628280-22-021061.json
- Plain text: https://secwatch.observer/filing/0001628280-22-021061.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.